HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Beam Therapeutics

Beam Therapeutics

BEAM

0.00

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ: BEAM) with a Buy and maintains $80 price target.